World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
124
Citations
58048
World Ranking
3221
National Ranking
89

Overview

Isabelle Ray-Coquard is affiliated with Claude Bernard University Lyon 1 in France, with a primary focus on medical research related to oncology and reproductive medicine. Their extensive body of work spans across multiple subfields including oncology, reproductive medicine, obstetrics and gynecology, molecular biology, and pulmonary and respiratory medicine.

The scientist's research addresses key topics such as ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, endometrial and cervical cancer treatments, sarcoma diagnosis and treatment, uterine myomas and treatments, DNA repair mechanisms, and BRCA gene mutations in cancer.

Frequent coauthors collaborating with Isabelle Ray-Coquard include Nicoletta Colombo, Jean-Yves Blay, Ignace Vergote, Éric Pujade-Lauraine, and Isabelle Treilleux.

Their research has appeared in various academic journals, with a strong presence in the following venues:

  • International Journal of Gynecological Cancer
  • Gynecologic Oncology
  • Cancers
  • Annals of Oncology
  • European Journal of Cancer

Notable recent publications include:

  • Endometrial cancer, 2021, Nature Reviews Disease Primers
  • ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer, 2020, Annals of Oncology
  • Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial, 2021, The Lancet Oncology
  • The forefront of ovarian cancer therapy: update on PARP inhibitors, 2020, Annals of Oncology
  • Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, 2023, Annals of Oncology

With a research output including over 660 publications primarily in the field of medicine, Isabelle Ray-Coquard has contributed significantly to the understanding and treatment of gynecological cancers and related conditions.

Best Publications

  • Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

    Eric Pujade-Lauraine;Jonathan A Ledermann;Frédéric Selle;Val Gebski

  • Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).

    Andreas du Bois;Alexander Reuss;Eric Pujade-Lauraine;Philipp Harter

  • Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

    Eric Pujade-Lauraine;Felix Hilpert;Beatrice Weber;Alexander Reuss

  • Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

    Isabelle Ray-Coquard;Patricia Pautier;Sandro Pignata;David Pérol

  • Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

    Elizabeth M Swisher;Kevin K Lin;Amit M Oza;Clare L Scott

  • Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

    Jean Yves Blay;Sylvie Bonvalot;Paolo Casali;Haesun Choi

  • ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

    N. Colombo;C. Sessa;A. du Bois;J. Ledermann

  • Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome

    Michael Gobert;Isabelle Treilleux;Nathalie Bendriss-Vermare;Thomas Bachelot

  • Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

    Thomas Bachelot;Céline Bourgier;Claire Cropet;Isabelle Ray-Coquard

  • Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer―Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

    Stefan Sleijfer;Isabelle Ray-Coquard;Zsuzsa Papai;Axel Le Cesne

  • Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

    Isabelle Ray-Coquard;Claire Cropet;Martine Van Glabbeke;Catherine Sebban

  • Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.

    Julia Bohlius;Kurt Schmidlin;Corinne Brillant;Guido Schwarzer

  • Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.

    Isabelle Ray-Coquard;Jean-Yves Blay;Antoine Italiano;Axel Le Cesne

  • Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study

    Nicolas Penel;Binh Nguyen Bui;Jacques-Olivier Bay;Didier Cupissol

  • Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing

    Françoise Ducimetière;Antoine Lurkin;Dominique Ranchère-Vince;Anne-Valérie Decouvelaere

  • Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Paolo G. Casali;Jean-Yves Blay;Alexia Bertuzzi;Stefan Bielack

  • Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial

    A. Le Cesne;J.Y. Blay;I. Judson;A. Van Oosterom

  • Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group

    Jean-Yves Blay;Axel Le Cesne;Isabelle Ray-Coquard;Binh Bui

  • ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.

    N Colombo;N Colombo;C Sessa;A du Bois;J Ledermann

  • Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3

    Andreas du Bois;Alexander Reuss;Eric Pujade-Lauraine;Philipp Harter

Frequent Co-Authors

Jean-Yves Blay
Jean-Yves Blay Claude Bernard University Lyon 1
Axel Le Cesne
Axel Le Cesne Institut Gustave Roussy
Antoine Italiano
Antoine Italiano University of Bordeaux
François Bertucci
François Bertucci Aix-Marseille University
Christine Chevreau
Christine Chevreau DuPont (United States)
Jean-Michel Coindre
Jean-Michel Coindre University of Bordeaux
Nicoletta Colombo
Nicoletta Colombo University of Milano-Bicocca
Ana Oaknin
Ana Oaknin Vall d'Hebron Hospital Universitari
Sandro Pignata
Sandro Pignata National Cancer Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering studying Medicine in the USA, there are several related online degrees and career pathways that could broaden your skills and open up new opportunities. Many students look to fields like healthcare administration, pharmacy, or advanced nursing to complement their medical education.

Pursuing a health care administration online degree can prepare you for leadership roles in hospitals, clinics, and other medical facilities. For those seeking specialized management positions, there are also most affordable mha programs that offer comprehensive training in healthcare policy, finance, and operations.

Nursing professionals interested in clinical leadership might explore cheap online dnp programs, which provide a pathway to the highest levels of nursing practice. Additionally, for those fascinated by pharmaceuticals and patient care, a 3-year online pharmd program can help you earn your Doctor of Pharmacy credentials more flexibly and affordably.

These degrees offer flexible study options, affordability, and career advancement in various healthcare sectors—important factors to consider on your journey in medicine.

Best Scientists Citing Isabelle Ray-Coquard

Trending Scientists